Profile data is unavailable for this security.
About the company
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
- Revenue in SEK (TTM)743.21m
- Net income in SEK573.47m
- Incorporated2014
- Employees31.00
- LocationSaniona ABSmedeland 26BGLOSTRUP 2600DenmarkDNK
- Websitehttps://saniona.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MindMaze Therapeutics Holding SA | 47.12m | -198.06m | 1.98bn | 31.00 | -- | 0.4124 | -- | 41.99 | -1.36 | -1.36 | 0.3231 | 2.59 | 0.0682 | 2.49 | 2.75 | 130,774.20 | -28.66 | -33.04 | -30.87 | -35.76 | 60.24 | -- | -420.33 | -874.66 | 3.80 | -49.62 | 0.055 | -- | 39.52 | -- | 82.56 | -- | -- | -- |
| Selvita SA | 940.25m | -7.28m | 2.00bn | 434.00 | -- | 2.51 | 15.05 | 2.13 | -0.1577 | -0.1577 | 20.37 | 17.23 | 0.5983 | 8.96 | 4.97 | 398,187.40 | -0.4629 | 5.76 | -0.5715 | 7.33 | 80.27 | 80.65 | -0.7737 | 8.57 | 0.8823 | 0.7538 | 0.3757 | -- | -1.73 | -- | -108.73 | -- | -- | -- |
| Cereno Scientific AB | 0.00 | -113.30m | 2.01bn | 5.00 | -- | 9.83 | -- | -- | -0.3987 | -0.3987 | 0.00 | 0.6572 | 0.00 | -- | -- | -- | -30.72 | -20.10 | -32.58 | -21.72 | -- | -- | -- | -- | -- | -1.94 | 0.4817 | -- | -- | -- | -106.89 | -- | 47.93 | -- |
| Diamyd Medical AB | 348.00k | -182.46m | 2.28bn | 41.00 | -- | 10.09 | -- | 6,545.81 | -1.52 | -1.52 | 0.0029 | 1.68 | 0.0013 | -- | 18.81 | 8,923.08 | -69.46 | -44.47 | -76.54 | -49.74 | -- | -- | -52,430.46 | -31,802.45 | -- | -- | 0.1628 | -- | 0.00 | -17.54 | -11.81 | -- | 38.40 | -- |
| Transgene SA | 76.66m | -389.50m | 2.47bn | 147.00 | -- | -- | -- | 32.19 | -0.1456 | -0.1456 | 0.0618 | -0.0272 | 0.1578 | -- | 8.72 | 43,872.73 | -80.19 | -33.32 | -186.71 | -40.55 | -- | -- | -508.10 | -251.37 | -- | -17.28 | 1.13 | -- | -20.34 | -14.48 | -52.15 | -- | 12.68 | -- |
| Cellectis SA | 736.66m | -315.47m | 2.52bn | 224.00 | -- | 2.82 | -- | 3.43 | -0.297 | -0.297 | 0.6916 | 1.17 | 0.2234 | -- | 8.58 | 310,550.20 | -9.57 | -21.50 | -16.65 | -29.24 | -- | -32.79 | -42.82 | -220.86 | -- | -3.13 | 0.5013 | -- | 435.37 | 16.44 | 66.41 | -- | -21.58 | -- |
| Eurobio Scientific SA | 1.72bn | 25.01m | 2.61bn | 380.00 | 102.51 | 1.33 | 13.83 | 1.52 | 0.2346 | 0.2346 | 15.76 | 18.03 | 0.5651 | 1.62 | 5.21 | 497,196.30 | 0.8231 | 14.00 | 1.02 | 17.37 | 23.69 | 51.40 | 1.46 | 20.70 | 1.25 | 1.72 | 0.0845 | 0.00 | 18.89 | 21.21 | -17.31 | 4.86 | 15.38 | -- |
| Oryzon Genomics SA | 0.00 | -28.08m | 2.66bn | 47.00 | -- | 2.09 | -- | -- | -0.0406 | -0.0406 | 0.00 | 1.51 | 0.00 | 95.26 | -- | 0.00 | -2.08 | -3.91 | -2.37 | -4.48 | -- | -- | -- | -- | 2.13 | -8.64 | 0.0725 | -- | -- | -- | -9.32 | -- | -4.26 | -- |
| Vicore Pharma Holding AB | 8.50m | -424.45m | 3.00bn | 36.00 | -- | 3.13 | -- | 352.36 | -1.85 | -1.85 | 0.0371 | 3.40 | 0.0134 | -- | 2.04 | 293,137.90 | -66.65 | -49.13 | -71.78 | -54.58 | -- | -- | -4,992.90 | -1,107.81 | -- | -35.34 | 0.00 | -- | -- | -- | 45.77 | -- | -- | -- |
| Avacta Group Plc | -135.09m | -402.99m | 3.11bn | 151.00 | -- | 1,585.70 | -- | -- | -0.0891 | -0.1579 | -0.0298 | 0.0004 | -0.1872 | -- | -- | -73,456.95 | -55.83 | -43.48 | -129.38 | -78.27 | -- | 63.54 | -- | -781.44 | 0.7883 | -0.4837 | 0.993 | -- | -96.04 | -- | -0.9503 | -- | -- | -- |
| Saniona AB | 743.21m | 573.47m | 3.49bn | 31.00 | 5.50 | 5.07 | 6.02 | 4.70 | 4.60 | 4.60 | 5.98 | 5.00 | 1.75 | -- | 121.92 | 33,782,040.00 | 135.23 | -38.47 | 170.81 | -45.71 | 90.13 | -55.15 | 77.16 | -156.43 | -- | -- | 0.0004 | -- | 1,887.36 | 115.50 | 296.96 | -- | -48.69 | -- |
| Genfit SA | 480.88m | -410.46m | 3.78bn | 188.00 | -- | 6.79 | -- | 7.86 | -0.7737 | -0.7737 | 0.9083 | 1.05 | 0.2207 | 519.75 | 0.9236 | 252,277.80 | -18.84 | -7.73 | -23.25 | -9.79 | 95.42 | 95.68 | -85.35 | -37.15 | 3.74 | -10.87 | 0.1223 | -- | 85.82 | 11.61 | 105.22 | -- | -13.57 | -- |
| Puretech Health PLC | 57.03m | 452.23m | 3.78bn | 56.00 | 8.47 | 1.12 | 12.00 | 66.34 | 0.1518 | 0.1518 | 0.0194 | 1.15 | 0.0113 | -- | 2.81 | 83,620.53 | 5.63 | -3.27 | 6.57 | -3.83 | -- | -- | 498.87 | -253.25 | -- | -- | 0.0537 | -- | 44.98 | -13.21 | 181.45 | -33.81 | -75.53 | -- |
| Hansa Biopharma AB | 222.27m | -529.25m | 4.07bn | 125.00 | -- | -- | -- | 18.31 | -6.44 | -6.44 | 2.73 | -0.8268 | 0.226 | 19.12 | 2.24 | 1,778,120.00 | -53.80 | -57.18 | -81.36 | -73.22 | 62.41 | 60.32 | -238.12 | -464.70 | 1.92 | -- | 1.10 | -- | 29.74 | 105.28 | 34.44 | -- | -- | -- |
| Formycon AG | 548.32m | -1.80bn | 4.45bn | 245.00 | -- | 1.03 | -- | 8.12 | -9.60 | -9.60 | 2.93 | 23.12 | 0.0613 | 31.72 | 1.91 | 207,112.00 | -20.09 | -1.47 | -21.17 | -1.58 | -0.9927 | 25.54 | -327.88 | -13.00 | 1.51 | -1.27 | 0.0244 | -- | -10.32 | 15.48 | -265.81 | -- | 96.87 | -- |
| Newron Pharmaceuticals SpA | 633.84m | 268.09m | 4.62bn | 22.00 | 15.98 | 275.10 | 17.11 | 7.29 | 1.24 | 1.24 | 2.83 | 0.0722 | 1.39 | -- | 11.69 | 2,478,738.00 | 58.67 | -23.70 | 123.93 | -32.05 | 98.17 | 97.14 | 42.30 | -69.33 | -- | 8.56 | 0.9708 | -- | 467.41 | 48.83 | 197.65 | -- | -23.92 | -- |
Data as of Feb 13 2026. Currency figures normalised to Saniona AB's reporting currency: Swedish Krona SEK
7.48%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| American Century Investment Management, Inc.as of 08 Jan 2026 | 3.23m | 2.34% |
| Tredje AP-fondenas of 29 Jul 2024 | 3.09m | 2.24% |
| Handelsbanken Fonder ABas of 31 Dec 2024 | 1.84m | 1.34% |
| SEB Funds ABas of 31 Dec 2025 | 1.05m | 0.76% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 497.21k | 0.36% |
| Skandia Investment Management ABas of 28 Nov 2025 | 277.18k | 0.20% |
| Alphajet Fair Investors SASas of 03 Feb 2026 | 220.00k | 0.16% |
| Velten Asset Management GmbHas of 28 Nov 2025 | 66.27k | 0.05% |
| Lazard Asset Management LLCas of 31 Jan 2026 | 59.03k | 0.04% |
| SSgA Funds Management, Inc.as of 08 Jan 2026 | 5.24k | 0.00% |
More ▼
Data from 30 Sep 2025 - 03 Feb 2026Source: FactSet Research Systems Inc.
